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Introduction 
 
The United Nations Environment Program (UNEP)/SETAC Life Cycle Initiative aims at putting 
life cycle thinking into practice and at improving the supporting tools for this process through 
better data and indicators. The initiative has thus launched three programs with associated 
working groups (see http://www.uneptie.org/pc/sustain/lcinitiative/). The Task Force on Toxic 
Impacts was established under the Life Cycle Impact Assessment (LCIA) program to establish 
recommended practice and guidance for use in human toxicity, ecosystem toxicity, and related 
categories with direct effects on human health and ecosystem health.  
 
During the 2004 SETAC Europe meeting in Prague, an international group of LCIA practitioners 
initiated activities of the LCIA Task Force 3 (TF3) to address exposure and toxicity with the goal 
of establishing guidance for LCIA. As an adjunct activity of the 2004 SETAC World Congress 
in Portland, Oregon, TF3 members organized a workshop to review existing proposals on human 
toxicity indicators for LCIA. The particular focus of this workshop was on options regarding 
dose-effect response and severity. The review workshop consisted of formal presentations of 
approaches followed by a review discussion performed by a panel of internationally recognized 
dose-response modeling experts. This workshop was organized by Thomas McKone of the 
University of California, Berkeley and Michael Hauschild and Stig Irving Olsen from the Danish 
Technical University in Denmark. Amy Kyle of the University of California, Berkeley, 
facilitated the workshop.  This workshop involved several internationally recognized dose-
response modeling experts as well as LCIA specialists (see footnote for the full list). The product 
of this workshop is a set of short recommendations that are being transmitted via this report. 
 
                                                 
1 Besides the authors, other workshop participants were: Lois Swirsky Gold, University of California, Berkeley, CA USA, 
Lorenz Rhomberg, Reviewer, Gradient Corporation, Cambridge, MA USA, Glenn Suter, US Environmental Protection Agency, 
Cincinnati, OH, USA, Jane Bare, US Environmental Protection Agency, Thomas Gloria, Five Winds International, Stefanie 
Hellweg, Swiss Federal Institute of Technology (ETH), Zürich, Switzerland, Allan Astrup Jensen, Force Technology, Denmark, 
Randy Maddalena, Lawrence Berkeley National Laboratory, Guido Sonnemann, Division of Technology, Industry & 
Economics, United Nations Environment Programme, Paris, France, Dik van de Meent, Member, RIVM Laboratory for 
Ecological Risk Assessment, Bilthoven, The Netherlands. 
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Workshop Format 
 
The workshop consisted of three elements. 
(A) presentations summarizing (1) the goals of the LCIA Task Force (2) historical 
approaches to exposure and toxic impacts in LCIA (3) current alternative proposals for 
addressing human health impacts. Viewgraphs from two of these presentations are 
provided in Appendix B to this report. 
(B) Discussion among a panel of experts about the scientific defensibility of these historical 
and proposed approaches in the context of the goals of the LCIA Task Force 3 on 
toxicity impacts. 
(C) Development of the recommendations to the LCIA program and working group for 
optimum short- and long-term strategies for addressing human health impacts in LCA. 
 
 
Background and Key References 
 
Life cycle assessment (LCA) is a framework for comparing products (or product-related 
emissions) according to their total estimated environmental impact summed over all chemical 
emissions and activities associated with the product’s life cycle.  To assess human toxicity 
impact, the LCIA practitioner considers for each chemical involved the cumulative exposure 
associated with the mass released to a defined (indoor, urban, regional, etc.) environment by 
multiplying the release amount by a measure of toxic impact to characterize the likelihood of 
health effects and their potential consequences.  
 
The SETAC Life Cycle Impact Assessment (LCIA) Working Group on Human Toxicity 
(Krewitt et al., 2002) have classified measures of toxic impact into two broad categories: 
(1) potency-based characterization factors that are used to assess the likelihood of a disease or 
effect (cancer, death, reproductive failure, etc) and (2) severity-based characterization factors or 
damage factors that, in addition to the qualitative or quantitative likelihood of disease, reflect 
population consequences of the disease in terms of years of life loss or some other measure of 
societal impact. But rather than indicating the likelihood of disease, potency mainly indicates a 
dose that has an effect (the effect dose or ED) or the lower confidence on the ED (Gold et al., 
2003). Recently, Crettaz et al. (2002) and Pennington et al. (2002) have proposed for both 
cancer and non-cancer health impacts in LCIA alternative approaches that include elements of 
both the potency and severity impact measures note above. For carcinogens, Crettaz et al. (2002) 
based their approach on the maximum likelihood estimate of the dose inducing a 10% response 
over background (the ED10) and derive from this a linear low-dose extrapolation using the slope 
0.1/ED10. They obtain the ED10 values by using the US EPA Integrated Risk Information 
System (IRIS), the medium tumor dose rate (TD50) from the Cancer Potency database of Gold et 
al. (2006), or data on median single lethal dose (LD50).  Potential consequences and severity are 
addressed by combining the low-dose slope with a measure of disability adjusted life years lost 
due to cancer to obtain a aggregate number of disability adjusted life years (DALYs) attributable 
to a specified chemical release.  For non-carcinogens Pennington et al. (2002) follow an 
approach similar to that of Crettaz et al. (2002), but made use of the benchmark dose to obtain a 
low-dose slope factor for non-cancer diseases.  
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Review Questions 
 
The workshop organizers provided a set of review questions in advance to both the experts and 
other workshop participants.  With regard to dose-response modeling in LCIA, the workshop 
organizers structured these review questions into five categories (Table 1)—general issues, 
measures of potency, species and population extrapolation, measures of severity, and data 
quality and availability. 
 
Table 1: Questions addressed by the review workshop 
1. General issues 
What is the scientific evidence for classifying any substance as a human carcinogen? 
What is the scientific evidence for classifying any substance as inducing some type of non-
cancer disease impact such as neurotoxicity, reproductive toxicity, respiratory irritation, 
developmental delay, asthma, autoimmune diseases, etc.? 
What is the validity and utility of using non-threshold linear dose-response models for 
assessing either cancer or non-cancer population disease burden?  
Are disability adjusted life years (DALYs) an appropriate endpoint measure of disease burden 
for life-cycle impact? 
Are there alternatives to DALYs that should be considered? 
Should we consider individual or population (collective) risk as a measure of impact in life-
cycle assessment? 
When combining the effects from exposures to multiple harmful substances, should we 
consider effect additivity, risk additivity, or cumulative disease burden in a measure of 
human health impact for LCA? 
 
2. Measures of potency 
What is the basis for the potency measure (e.g. critical effect, most severe effect, etc.)? 
Should carcinogens and non-carcinogens be separated when calculating health impact 
midpoints and/or health impact endpoints? 
For non-cancer outcomes should the midpoint and/or endpoint measure of disease burden 
make use of no adverse/lowest adverse effect (NOAEL/LOAEL) doses or benchmark doses 
(e.g. TD50, ED10)?  
For cancer outcomes should the midpoint and/or endpoint be based on slope factors or other 
potency measures such as benchmark dose? 
 
3. Species and population extrapolation 
In developing dose-response and disease burden models, should we apply extrapolation 
factors to account for differences between animals and humans, between sensitive 
subpopulations, etc.? 
If we use extrapolation factors, how should the extrapolation factors be derived, e.g. 
probabilistic methods or some set of default assumptions? 
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4. Measures of severity 
Should and how can LCIA models of toxicity include the severity of the effect? 
Should severity assessment be qualitative (indicator-based), semi-quantitative, or 
quantitative? 
If the measure of severity is quantitative: should the model include full damage modeling, that 
is both morbidity and mortality, and how should mortality and morbidity be aggregated? 
Should the model include partial damage modeling (e.g. only mortality)?  
What methods of damage modeling should be used? 
If the measure of severity is semi-quantitative or qualitative, what approach should be used to 
categorize and/or classify severity?  
 
5. Data quality and availability 
Can and how should data quality for human health impact and disease burden be quality 
assured?  
Are both experimental data and derived “safe” levels such as allowable daily intake (ADI) 
and reference dose (RfD) from the EPA IRIS database etc. available for a broad set of 
chemicals?  
What is the minimum level of data availability required to establish the lethal dose for 50% of 
a population (LD50), NOAEL, and/or benchmark doses from chronic studies?  
 
 
 
Workshop Findings 
 
The workshop findings are organized into three categories—overarching issues, measures of 
potency, and measures of severity. 
 
Overarching Issues: 
In concurrence with other workshop participants, the dose-response experts concluded that it 
is appropriate to include human toxicity in the LCIA process.  The basis for this 
recommendation is that, in the absence of a toxicity metric, many LCIA practitioners will 
continue to rely on emissions magnitude as a measure of emissions impact. But, because of 
the significant differences among chemicals in the dose levels that are toxic, it is essential to 
consider human toxicity in comparing releases of different toxic chemicals.   
There is an overarching concern that the LCIA process should address toxicity but limit the 
level of detail in the analysis to information that provides benefits or value to the overall 
LCIA.  Too much detail can reduce the transparency and reliability of the LCIA.  However, 
there may be cases where more analysis matters.  That is, cases where exposure is below a 
threshold of effect and for which more details on the distribution of population exposure will 
impact estimates of disease burden.   
 Page 5
 
 
 
Measures of Potency  
The expert panel recommended the use of a hierarchy of toxicity values in LCIA with 
priorities assigned so that LCIA assessors can evaluate the relative advantages of different 
toxicity metrics. The goal is to allow LCIA assessors to determine which metrics would be 
scientifically defensible and informative as well as identifying methods that are transparent 
and easy to use.  With regard to measures of potency, the workshop participants made the 
following specific recommendations. 
a) Human preference: Relevant and applicable human data should be given priority wherever 
such data are available. 
b) Preference for benchmark measures: The review panel preferred the use of benchmark 
measures of effect as a means of scaling relative toxicity, rather than a no observed adverse 
effect level (NOAEL), lowest observed adverse effect level (LOAEL) or Reference Dose 
(RfD), which is derived from NOAEL or LOAEL. Benchmark measures include the ED10, 
the dose that results in a toxic effect to 10% of the exposed population, and the ED50, the 
dose that results in a toxic effect to 50% of the exposed population. The basis for this 
recommendation is the frequent dependence of the NOAEL or LOAEL on the limitations 
of study design.  However, the experts expressed the view that it would be better to use the 
NOAEL or LOAEL rather than no measure at all, as a basis to estimate ED10 or ED50. 
Given the overall uncertainties, there are large differences between these alternate 
approaches in ranking chemicals in LCIA.  RfD values are obtained from NOAELs or 
LOAELs using safety or uncertainty factors that reflect differing degrees of precaution or 
protection. As a result, it is not clear whether the RfD, which was developed to provide an 
adequate margin of safety, can provide the consistent measure of harm needed in LCIA. 
Thus, when an RfD is used in chemical ranking, the panel recommended that the 
uncertainty measures used and the corresponding NOAEL or LOEL should be separated 
out from the RfD and reported along with the RfD.  
As a follow-up issue, the panel identified the need to come to a conclusion about whether 
an ED10 value, an ED50 value, some other benchmark (ED25), or some approach that 
combines these benchmark doses would be best suited to LCIA. The ED50 is at the median 
of the range of doses that produce significant results. The advantages of the ED50 are that 
it is a more stable measure and represents the point most comparable among biological 
species. The ED10 is usually within the dose range tested for statistically significant 
results. The advantage of the ED10 is that the information about slope or dose-response 
that is most chemical specific is between the ED50 and ED10 range, and this is better 
captured in the ED10. But the use of ED10 will not automatically reduce the level of 
uncertainty for low dose extrapolation.  If a practitioner believes that “slope” values from 
animal studies predict human values, this would argue for using the ED10. But this is a 
question that requires further research and for which we do not yet know the answer.   
A related need is to determine how to make use of combinations of ED50 and ED10 and 
possibly LOAEL and NOAEL in life-cycle impact rankings.  The experts recognized that 
when these different measures are combined there is a need for correction factors to make 
them consistent, to correct for data from different species, and to correct for differences in 
duration of the experimental exposures. The correction factors should be used to steer all 
values to best estimates as opposed to the most health protective values.  It is important to 
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avoid introducing bias even with methods that are consistent.  There is a need to include a 
larger number of chemicals in studies of correlation among the different measures of 
toxicity that were discussed at the workshop. 
c) Complexity of multi-chemical comparison and low dose extrapolation: The complexities of 
the analysis make it somewhat difficult to understand how the various dose-response 
methods might compare with respect to the value of information they provide to an LCIA.  
This problem derives in large part from differences among the methods of low dose 
extrapolation. LCIA involves comparisons among the life cycles of products not 
comparisons among the life cycle of chemicals. But even though this leads to comparisons 
among chemicals, LCIA is more complicated than single chemical comparisons.  
Moreover, the problem is one of multi-dimensional optimization.  This means that one 
input depends on others.  In LCIA we need a way to compare processes and activities that 
are not always comparable.  The need to confront and inform tradeoffs requires the ability 
to express relative preferences. 
d) Normalization: Normalization is a critical issue.  It is important to determine what to use as 
normalizing factor.  There are differences between normalizing to manmade changes and to 
natural background.  Global warming provides a cautionary example.  The discussion of 
the relative importance of environmental exposure as a cause of human health impacts and 
hence the relevance to address human toxic impacts in life cycle impact assessment lead to 
identification of a need for normalization against other types of impact.   
 
Measures of Severity 
With regard to measures of severity, the workshop participants made the following specific 
recommendations. 
a) Relation between severity and potency: The expert panel noted the value of taking severity 
into account but hesitated to recommend specific methods to characterize severity. They 
took this position because the way that potency is addressed will bear on severity but is not 
yet fully decided in the LCIA literature. In other words, it is necessary and acceptable to 
address severity, but we need to work out the specifics of potency issues to decide how. 
The panel recognized that not using some measure of severity is the same as treating all 
outcomes as having equal severity.  When confronting severity, there may be some simple 
methods that are more applicable in some cases, such as distinguishing between 
carcinogens and non-carcinogens, but, such approaches will also mask real differences in 
some or many cases. On the other hand, the panel expressed concern that explicitly treating 
severity may imply that we know more than we do and that we can estimate severity better 
than is actually feasible.  We want to avoid this situation.   
b) Multiple effects: It may be appropriate to look at more than one outcome.  Similar to other 
approaches, the RfD approach looks for the critical effect, which is the one that may occur 
at the lowest dose. The panel noted that this involves toxicity testing that is carried out to 
find the lowest level that produces an effect rather than completing a whole battery of tests 
at higher doses. This is appropriate when looking for a “safe” dose but may not be 
appropriate when trying to characterize representative impacts or the DALY burden on a 
population. More severe or more common outcomes that are not the ones that occur at the 
lowest dose may also be important. With only critical effects testing it is not possible to 
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obtain information on more severe outcomes that occur at higher doses. It may be very 
important to include a very common but not very severe outcome or a rare but very severe 
outcome.  Thus, there is a need to develop methods to address these concerns.  
c) Aggregation: There are aspects of toxic impacts that should be aggregated and other 
aspects that should be kept disaggregated.  There could be elements of severity that fit 
both.  In contrast to policy assessors, modeling/methods experts may have different needs 
in regard to the issue of aggregation. 
If we are going to put a valuation on an endpoint, it is important to be transparent.  The 
experts expressed concerns about DALYs because they represent one judgment about the 
significance of various health outcomes but these judgments may not be those of the target 
audience and may not have an established empirical basis. Thus, along with DALYs the 
analyst should report separately intermediate results such as Years of Life Lost (YOL) or 
years of life disabled. Additional weighting coefficients should be reported in a transparent 
way. 
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